|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HFM1 |
Gene summary for HFM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HFM1 | Gene ID | 164045 |
| Gene name | helicase for meiosis 1 | |
| Gene Alias | MER3 | |
| Cytomap | 1p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A2PYH4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 164045 | HFM1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.45e-05 | 2.00e-01 | 0.0155 |
| 164045 | HFM1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.26e-17 | 5.40e-01 | -0.1808 |
| 164045 | HFM1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.01e-08 | 9.04e-01 | 0.0216 |
| 164045 | HFM1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.15e-13 | 7.32e-01 | -0.0811 |
| 164045 | HFM1 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.43e-12 | 3.38e-01 | -0.1088 |
| 164045 | HFM1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.48e-33 | 6.14e-01 | -0.1954 |
| 164045 | HFM1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.83e-04 | 3.96e-01 | -0.2602 |
| 164045 | HFM1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.35e-10 | 8.74e-01 | -0.2196 |
| 164045 | HFM1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.53e-16 | 5.38e-01 | -0.1207 |
| 164045 | HFM1 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.55e-13 | 5.24e-01 | -0.1526 |
| 164045 | HFM1 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.32e-21 | 4.69e-01 | -0.1464 |
| 164045 | HFM1 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.14e-46 | 9.64e-01 | -0.1001 |
| 164045 | HFM1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.90e-33 | 8.84e-01 | -0.059 |
| 164045 | HFM1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.07e-21 | 9.63e-01 | -0.1706 |
| 164045 | HFM1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.40e-05 | 3.55e-01 | -0.2061 |
| 164045 | HFM1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.64e-18 | 8.85e-01 | -0.1462 |
| 164045 | HFM1 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.76e-10 | 4.07e-01 | -0.0842 |
| 164045 | HFM1 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.89e-04 | 3.96e-01 | -0.00410000000000005 |
| 164045 | HFM1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.61e-02 | 2.62e-01 | -0.0179 |
| 164045 | HFM1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.40e-18 | 5.33e-01 | 0.096 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032392 | Colorectum | AD | DNA geometric change | 31/3918 | 90/18723 | 2.02e-03 | 1.63e-02 | 31 |
| GO:00323921 | Colorectum | MSS | DNA geometric change | 29/3467 | 90/18723 | 1.26e-03 | 1.20e-02 | 29 |
| GO:0032508 | Colorectum | MSS | DNA duplex unwinding | 25/3467 | 84/18723 | 8.27e-03 | 4.99e-02 | 25 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HFM1 | SNV | Missense_Mutation | c.2428N>T | p.Val810Phe | p.V810F | A2PYH4 | protein_coding | tolerated(0.06) | benign(0.315) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HFM1 | SNV | Missense_Mutation | c.4229N>C | p.Val1410Ala | p.V1410A | A2PYH4 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HFM1 | SNV | Missense_Mutation | c.4187N>C | p.Lys1396Thr | p.K1396T | A2PYH4 | protein_coding | deleterious_low_confidence(0.02) | benign(0.04) | TCGA-C8-A1HO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| HFM1 | SNV | Missense_Mutation | c.310N>G | p.Leu104Val | p.L104V | A2PYH4 | protein_coding | deleterious_low_confidence(0.03) | benign(0.075) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| HFM1 | insertion | Frame_Shift_Ins | novel | c.2495_2496insTGCCTCAACA | p.Asn833AlafsTer24 | p.N833Afs*24 | A2PYH4 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| HFM1 | insertion | Frame_Shift_Ins | novel | c.3598_3599insTT | p.Asn1200IlefsTer29 | p.N1200Ifs*29 | A2PYH4 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| HFM1 | insertion | In_Frame_Ins | novel | c.3597_3598insTGTAATTTTCGT | p.Met1199_Asn1200insCysAsnPheArg | p.M1199_N1200insCNFR | A2PYH4 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| HFM1 | insertion | Frame_Shift_Ins | novel | c.577_578insGTTT | p.Ile193SerfsTer16 | p.I193Sfs*16 | A2PYH4 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| HFM1 | insertion | Frame_Shift_Ins | novel | c.576_577insC | p.Ile193HisfsTer15 | p.I193Hfs*15 | A2PYH4 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| HFM1 | SNV | Missense_Mutation | novel | c.1460G>T | p.Arg487Ile | p.R487I | A2PYH4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |